RayKnowChina Research Map
Shortlist

NanchangNanchang University

Second Affiliated Hospital of Nanchang University

南昌大学第二附属医院

Listed for 29 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Second Affiliated Hospital of Nanchang University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌14 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
  3. Hepatocellular carcinoma肝细胞癌96 papers led
  4. Stomach cancer胃癌57 papers led
  5. Lung cancer肺癌105 papers led5 open trials led
  6. Pancreatic cancer胰腺癌22 papers led
  7. Breast cancer乳腺癌19 papers led
  8. Glioma胶质瘤60 papers led
  9. Hepatoblastoma肝母细胞瘤1 paper led
  10. Retinoblastoma视网膜母细胞瘤2 papers led
  11. Osteosarcoma骨肉瘤26 papers led
  12. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  13. Neuroblastoma神经母细胞瘤1 paper led
  14. Multiple myeloma多发性骨髓瘤10 papers led
  15. Lymphoma淋巴瘤15 papers led1 open trial led
  16. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
  17. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  18. Moyamoya disease烟雾病3 papers led
  19. Wilson disease肝豆状核变性(Wilson 病)1 paper led
  20. Coronary heart disease冠心病21 papers led
  21. Congenital heart disease先天性心脏病11 papers led
  22. Takayasu arteritis大动脉炎0 papers led
  23. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  24. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  25. Duchenne muscular dystrophy杜氏肌营养不良2 papers led
  26. IgA nephropathyIgA 肾病10 papers led
  27. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  28. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  29. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Chordoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Biliary atresia, Scoliosis, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 14 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
14
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 3320242025: 662025

3 hospitals in Nanchang for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT05956587

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou

  2. Recruiting
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    Phase
    N/A
    Started
    2023-06
    Posted
    Registry
    NCT05892354

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical University; 13 listed hospitals as study sitesFuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Liuzhou, Nanchang, Nanning, Wuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueSide effects & quality of lifeInduction / concurrent chemotherapy
Departments in papersMedical oncologyENT / head & neck surgeryRheumatology & immunologyRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led14
  1. A comparative study of different parameter estimation methods for predictive models of Normal Tissue Complication Probability (NTCP) of radiation-induced temporal lobe injury following intensity-modulated radiotherapy in nasopharyngeal carc2025BMC cancerFree full text
  2. Role of Coiled-Coil Domain-Containing Protein 86 in Tumorigenesis of Nasopharyngeal Carcinoma.2025Bulletin of experimental biology and medicine
  3. Pre-treatment serum apolipoprotein E: a promising prognostic indicator for nasopharyngeal carcinoma.2025European journal of medical researchFree full text
  4. ETV5 transcriptionally activates LGR4 and promotes cancer cell invasion and migration of nasopharyngeal carcinoma.2025Journal of molecular histology
  5. ANLN knockdown inhibits nasopharyngeal carcinoma proliferation and is associated with impaired ribosome biogenesis.2025Neoplasma
  6. The NSUN2-YBX1 axis enhances 5-Methylcytosine modification to facilitate NPM1-mediated nuclear translocation of PKM2, augmenting the Warburg effect and promoting nasopharyngeal carcinoma progression in a mouse model.2025Rhinology
  7. A Neural Network-based Method for Predicting Dose to Organs at Risk in Intensity-modulated Radiotherapy for Nasopharyngeal Carcinoma.2024Clinical oncology (Royal College of Radiologists (Great Britain))
  8. Explore the shared molecular mechanism between dermatomyositis and nasopharyngeal cancer by bioinformatic analysis.2024PloS oneFree full text
  9. MiR-122-5p regulates erastin-induced ferroptosis via CS in nasopharyngeal carcinoma.2024Scientific reportsFree full text
  10. CCDC86 promotes the aggressive behavior of nasopharyngeal carcinoma by positively regulating EGFR and activating the PI3K/Akt signaling.2023Neoplasma
  11. Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  12. Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial.2022BMJ openFree full text
  13. A Prospective Study on Defining the Indications of Prophylactic Level IB Radiotherapy in Nasopharyngeal Carcinoma Based on a Risk Score Model.2022Oncology research and treatment
  14. Overexpression of HOXA10 promotes the growth and metastasis of nasopharyngeal carcinoma.2021Experimental biology and medicine (Maywood, N.J.)Free full text
All its trials on ClinicalTrials.gov, any status6
  1. Clarify of Predictive Risk Factors of Chemotherapy-induced Liver InjuryStatus unknownNCT03069820Lead sponsorPhase 4Start 2017-02
  2. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Study sitePhase 2Start 2024-01
  3. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After ChemoradiotherapyRecruitingNCT05892354Study siteN/AStart 2023-06
  4. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  5. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  6. Endostar for Locally Recurrent Nasopharyngeal CarcinomaStatus unknownNCT02636231Study sitePhase 2Start 2015-11
More papers found outside PubMed (not counted)3
  1. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  2. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract
  3. Risk Analysis of Severe Thrombocytopenia in Nasopharyngeal Carcinoma During Concurrent Radio-Chemotherapy2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 222025

3 hospitals in Nanchang for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsImaging & AI
Departments in papersPathology / laboratory medicine
Papers it led4
  1. AL137246.1 inhibits esophageal squamous cell carcinoma cisplatin resistance by suppressing the transcriptional activity of GLI2 on ABCC1.2025Molecular genetics and genomics : MGG
  2. ZCCHC4 regulates esophageal cancer progression and cisplatin resistance through ROS/c-myc axis.2025Scientific reportsFree full text
  3. Prognostic value and immune landscapes of cuproptosis-related lncRNAs in esophageal squamous cell carcinoma.2023AgingFree full text
  4. USP18 promotes tumor metastasis in esophageal squamous cell carcinomas via deubiquitinating ZEB1.2021Experimental cell research
All its trials on ClinicalTrials.gov, any status4
  1. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  2. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
  3. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  4. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
More papers found outside PubMed (not counted)3
  1. WITHDRAWN: 2143P Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: A multicenter, real-world, retrospective cohort study2025Annals of Oncologyretraction
  2. Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  3. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 96 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
96
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 121220212022: 161620222023: 222220232024: 202020242025: 22222025

3 hospitals in Nanchang for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Posted
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  2. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  3. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  4. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  5. Recruiting
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    Phase
    Not given
    Started
    2022-09
    Posted
    Registry
    NCT06822413

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

  6. Not yet recruiting
    Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07596134

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Nanchang, Taizhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyGastroenterology / hepatologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led96
  1. TMEM44 as a Novel Prognostic Marker for Hepatocellular Carcinoma is Associated with Tumor Invasion, Migration, and Apoptosis.2026Biochemical genetics
  2. NCAPG confers ferroptosis resistance of hepatocellular carcinoma through NSUN2-mediated m5C modification.2026Cellular signalling
  3. Diosgenin targets ITGA11-driven angiogenesis in hepatocellular carcinoma: Prognostic and mechanistic insights.2026Computational biology and chemistry
  4. BAG6 promotes hepatocellular carcinoma growth via enhancing PLK1-mediated aerobic glycolysis.2026International journal of biological macromolecules
  5. Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study.2025BMC cancerFree full text
  6. ACSM5 Regulates Ferroptosis in Hepatocellular Carcinoma by Up-Regulating POR and Modulating Lipid Metabolism.2025Cancer scienceFree full text
  7. SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma.2025Cell death & diseaseFree full text
  8. NUB1 reduction promotes PCNA-mediated tumor growth by disturbing the PCNA polyubiquitination/NEDDylation in hepatocellular carcinoma cells.2025Cell death & diseaseFree full text
  9. Elevated P4HB expression in hepatocellular carcinoma and its role in UCA1-mediated malignant progression.2025Cellular signalling
  10. NCAPG promotes epithelial-mesenchymal transition through SIP-dependent ubiquitination regulation of β-catenin in hepatocellular carcinoma.2025Cellular signalling
  11. AHCTF1 Functions as an Oncogenic Factor and Promotes Tumor Progression in Hepatocellular Carcinoma.2025Digestive diseases and sciencesFree full text
  12. XPD Regulates MIAT/miR-29a-3p/COL4A1 Axis to Impede Hepatocellular Carcinoma Development.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  13. Plasma exosomal lncRNA-related signatures define molecular subtypes and predict survival and treatment response in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  14. PSMD12 promotes hepatocellular carcinoma progression by stabilizing CDK1.2025Frontiers in immunologyFree full text
  15. DDX1 facilitates lenvatinib resistance in hepatocellular carcinoma through regulating ephrin-A3 and activating the Wnt/β-catenin signaling pathway.2025Functional & integrative genomics
  16. Rapid detection of plasma exosomal LncRNA CASC9 for HCC using RT-RPA-CRISPR/Cas12a assay.2025Journal of pharmaceutical and biomedical analysis
  17. High interstitial fluid pressure enhances USP1-dependent KIF11 protein stability to promote hepatocellular carcinoma progression.2025Journal of translational medicineFree full text
  18. METTL3-mediated TUG1 regulation of miR-9 in doxorubicin resistance in HCC.2025Life sciences
  19. Comprehensive Bioinformatics Analysis and Machine Learning of TTK as a Transhepatic Arterial Chemoembolization Resistance Target in Hepatocellular Carcinoma.2025Molecular biotechnology
  20. Mechanism of atorvastatin in treating hepatocellular carcinoma: a study based on network pharmacology, molecular docking, and bioinformatics analysis.2025Naunyn-Schmiedeberg's archives of pharmacology
  21. Modeling the prediction of spontaneous rupture and bleeding in hepatocellular carcinoma via machine learning algorithms.2025Scientific reportsFree full text
  22. The m6A reader IGF2BP3 promotes HCC progression by enhancing MCM10 stability.2025Scientific reportsFree full text
  23. hsa_circ_0008305 facilitates the malignant progression of hepatocellular carcinoma by regulating AKR1C3 expression and sponging miR-379-5p.2025Scientific reportsFree full text
  24. Multiomic characterization, immunological and prognostic potential of SMAD3 in pan-cancer and validation in LIHC.2025Scientific reportsFree full text
  25. Comparative efficacy and safety of lenvatinib, sintilimab combined interventional therapy vs bevacizumab, sintilimab combined interventional therapy in intermediate and advanced hepatocellular carcinoma: a multicenter retrospective study.2025World journal of surgical oncologyFree full text
  26. A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma with esophagogastric varices after progression on first-line lenvatinib combined with PD-1 inhibitor.2025World journal of surgical oncologyFree full text
  27. Comprehensive prognostic and immunological analysis of Cullin2 in pan-cancer and its identification in hepatocellular carcinoma.2024AgingFree full text
  28. Development of machine learning-based personalized predictive models for risk evaluation of hepatocellular carcinoma in hepatitis B virus-related cirrhosis patients with low levels of serum alpha-fetoprotein.2024Annals of hepatology
  29. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.2024Cancer medicineFree full text
  30. Ropivacaine synergizes with sorafenib to induce apoptosis of hepatocellular carcinoma cells via the IL-6/STAT3 pathway.2024Cancer scienceFree full text
  31. USP11 promotes lipogenesis and tumorigenesis by regulating SREBF1 stability in hepatocellular carcinoma.2024Cell communication and signaling : CCSFree full text
  32. SNRPB2 in the pan-cancer landscape: A bioinformatics exploration and validation in hepatocellular carcinoma.2024Cellular signalling
  33. PSMD11 promotes the proliferation of hepatocellular carcinoma by regulating the ubiquitination degradation of CDK4.2024Cellular signalling
  34. Ropivacaine combined with sorafenib attenuates hepatocellular carcinoma cell proliferation and metastasis by inhibiting the miR-224/HOXD10 axis.2024Environmental toxicology
  35. Knockdown of circZMIZ1 enhances the anti-tumor activity of CD8+ T cells to alleviate hepatocellular carcinoma.2024Functional & integrative genomics
  36. SRSF7 is a promising prognostic biomarker in hepatocellular carcinoma and is associated with immune infiltration.2024Genes & genomics
  37. The ubiquitin-like protein FAT10 in hepatocellular carcinoma cells limits the efficacy of anti-VEGF therapy.2024Journal of advanced researchFree full text
  38. Homeobox B9 promotes the invasion and metastasis of hepatocellular carcinoma cells via the EZH2-MIR203A-SNAI2 axis.2024Journal of translational medicineFree full text
  39. AC099850.3 promotes HBV-HCC cell proliferation and invasion through regulating CD276: a novel strategy for sorafenib and immune checkpoint combination therapy.2024Journal of translational medicineFree full text
  40. The HHEX-ABI2/SLC17A9 axis induces cancer stem cell-like properties and tumorigenesis in HCC.2024Journal of translational medicineFree full text
  41. BarH-Like Homeobox 2 Suppresses Cell Proliferation, Invasion, and Angiogenesis in Hepatocellular Carcinoma by Activating N-Acetylgalactosaminyltransferase 4.2024Molecular biotechnology
  42. Hepatic Symbiotic Bacterium L. reuteri FLRE5K1 Inhibits the Development and Progression of Hepatocellular Carcinoma via Activating the IFN-γ/CXCL10/CXCR3 Pathway.2024Probiotics and antimicrobial proteins
  43. Comparative analysis of the safety and feasibility of laparoscopic and open approaches for right anterior sectionectomy.2024Scientific reportsFree full text
  44. SNX16 is required for hepatocellular carcinoma survival via modulating the EGFR-AKT signaling pathway.2024Scientific reportsFree full text
  45. PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis.2024Technology in cancer research & treatmentFree full text
  46. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.2024World journal of surgical oncologyFree full text
  47. ZNF765 is a prognostic biomarker of hepatocellular carcinoma associated with cell cycle, immune infiltration, m6A modification, and drug susceptibility.2023AgingFree full text
  48. FARSB serves as a novel hypomethylated and immune cell infiltration related prognostic biomarker in hepatocellular carcinoma.2023AgingFree full text
  49. Comprehensive analysis reveals TSEN54 as a robust prognosis biomarker and promising immune-related therapeutic target for hepatocellular carcinoma.2023AgingFree full text
  50. Biological function analysis of ARHGAP39 as an independent prognostic biomarker in hepatocellular carcinoma.2023AgingFree full text
  51. Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China.2023BMC cancerFree full text
  52. Network meta-analysis of adjuvant treatments for patients with hepatocellular carcinoma after curative resection.2023BMC gastroenterologyFree full text
  53. Signature construction and molecular subtype identification based on immune-related genes for better prediction of prognosis in hepatocellular carcinoma.2023BMC medical genomicsFree full text
  54. Prognostic value and immune landscapes of immunogenic cell death-related lncRNAs in hepatocellular carcinoma.2023Bioscience reportsFree full text
  55. Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer.2023Canadian journal of gastroenterology & hepatologyFree full text
  56. The deubiquitinating enzyme USP44 suppresses hepatocellular carcinoma progression by inhibiting Hedgehog signaling and PDL1 expression.2023Cell death & diseaseFree full text
  57. CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma.2023Current oncology (Toronto, Ont.)Free full text
  58. Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework.2023European journal of medical researchFree full text
  59. Validation of a supplementary condition of eighth AJCC staging system for stage II hepatocellular carcinoma.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  60. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  61. Molecular subtype identification and signature construction based on Golgi apparatus-related genes for better prediction prognosis and immunotherapy response in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  62. Comprehensive bioinformatics analysis of a RBM family-based prognostic signature with experiment validation in hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  63. Biejia-Ruangan compound and incidence of hepatocellular carcinoma.2023Journal of hepatology
  64. NOP2-mediated m5C methylation of XPD is associated with hepatocellular carcinoma progression.2023Neoplasma
  65. Identification of M2-like macrophage-related signature for predicting the prognosis, ecosystem and immunotherapy response in hepatocellular carcinoma.2023PloS oneFree full text
  66. LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-L1 expression.2023Scientific reportsFree full text
  67. Pancancer analysis of oncogenic BARX2 identifying its prognostic value and immunological function in liver hepatocellular carcinoma.2023Scientific reportsFree full text
  68. Based on the IWATE criteria: to investigate the influence of different surgical approaches on the perioperative outcomes of hepatectomy.2023Surgical endoscopy
  69. Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma.2022AgingFree full text
  70. Desmocollin-2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma via the ERK/c-MYC signaling pathway.2022AgingFree full text
  71. ZNF320 is a hypomethylated prognostic biomarker involved in immune infiltration of hepatocellular carcinoma and associated with cell cycle.2022AgingFree full text
  72. Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1.2022BioengineeredFree full text
  73. TP53 mutation detected in circulating exosomal DNA is associated with prognosis of patients with hepatocellular carcinoma.2022Cancer biology & therapyFree full text
  74. O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease.2022CellsFree full text
  75. MiR-27a-3p targets USP46 to inhibit the cell proliferation of hepatocellular carcinoma.2022Chemical biology & drug design
  76. A Pyroptosis-Related Gene Signature to Predict Patients' Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma.2022Computational and mathematical methods in medicineFree full text
  77. Identification of a Necroptosis-Related Prognostic Signature and Associated Regulatory Axis in Liver Hepatocellular Carcinoma.2022Disease markersFree full text
  78. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  79. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  80. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  81. NCAPG promotes the proliferation of hepatocellular carcinoma through the CKII-dependent regulation of PTEN.2022Journal of translational medicineFree full text
  82. miR-2392 serves as an immunological and prognostic biomarker in hepatocellular carcinoma.2022Liver international : official journal of the International Association for the Study of the Liver
  83. Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma.2022Molecular cancerFree full text
  84. DLGAP4 acts as an effective prognostic predictor for hepatocellular carcinoma and is closely related to tumour progression.2022Scientific reportsFree full text
  85. The deubiquitinase OTUD3 stabilizes ACTN4 to drive growth and metastasis of hepatocellular carcinoma.2021AgingFree full text
  86. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database.2021BMC cancerFree full text
  87. Modified median hepatic fissure approach for resection of liver tumours located in the angle between the root of the middle and right hepatic veins.2021BMC surgeryFree full text
  88. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.2021BioengineeredFree full text
  89. COL4A1, negatively regulated by XPD and miR-29a-3p, promotes cell proliferation, migration, invasion and epithelial-mesenchymal transition in liver cancer cells.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  90. Comparing the diagnostic value of serum oligosaccharide chain (G-test) and alpha-fetoprotein for hepatitis B virus-related liver cancer.2021Clinical biochemistry
  91. Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1.2021Experimental cell research
  92. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.2021Journal of cellular biochemistry
  93. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis.2021Journal of cellular physiology
  94. Silencing of ATG4D suppressed proliferation and enhanced cisplatin-induced apoptosis in hepatocellular carcinoma through Akt/Caspase-3 pathway.2021Molecular and cellular biochemistry
  95. Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance.2021Oncogene
  96. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.2021World journal of surgical oncologyFree full text
All its trials on ClinicalTrials.gov, any status14
  1. HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCCStatus unknownNCT05582278Lead (inferred)Phase 2Start 2021-01
  2. Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCCNot yet recruitingNCT07596134Study siteN/AStart 2026-10
  3. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  4. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  5. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  6. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  7. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early DiagnosisRecruitingNCT06822413Study siteStart 2022-09
  8. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)TerminatedNCT06487559Study sitePhase 1Start 2024-09
  9. Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)Status unknownNCT05594927Study sitePhase 3Start 2022-12
  10. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCCompletedNCT04948697Study sitePhase 2Start 2021-08
  11. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  12. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  13. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  14. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 57 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.6%.

Papers led
57
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 111120212022: 4420222023: 8820232024: 191920242025: 12122025

3 hospitals in Nanchang for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Posted
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  2. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  3. Recruiting
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    Phase
    Not given
    Started
    2022-09
    Posted
    Registry
    NCT06822413

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AIPeritoneal spread & advanced diseaseImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicineMedical oncology
Papers it led57
  1. A Network Information-Based Behavior Change Wheel for Populations at High Risk of Developing Gastric Cancer.2026Journal of cancer education : the official journal of the American Association for Cancer Education
  2. The Role of Yes-Associated Protein in Autophagy and Tumor Progression in Gastric Cancer.2026Molecular biotechnology
  3. P2Y2 receptor as a favorable predictor of gastric cancer.2026Tissue & cell
  4. MR Promotes Ferroptosis in Gastric Cancer by Regulating FANCD2 Expression Mediated by m6A Modification.2025Applied biochemistry and biotechnology
  5. Comprehensive analysis of ferroptosis-related long non-coding RNA and its association with tumor progression and ferroptosis in gastric cancer.2025BMC gastroenterologyFree full text
  6. Methionine Restriction Exerts Anti-Tumor Immunity via Joint Intervention of T-Bet Palmitoylation in Gastric Cancer.2025Biotechnology journal
  7. Lectin-affinity glycosylation pattern analysis of plasma extracellular vesicles: An all-in-one clinical assessment for gastric cancer diagnosis and treatment.2025Cancer letters
  8. HNF4A promotes tumor progression in gastric cancer by transcriptional activation of KIF2C.2025Clinical and experimental medicineFree full text
  9. Skeletal muscle gauge: A superior predictor of neoadjuvant chemoimmunotherapy efficacy in locally advanced gastric cancer.2025Clinical nutrition ESPEN
  10. TFAP4 Regulation of MCM5 Activates the PI3K/AKT Pathway to Promote Invasion and Metastasis of Gastric Cancer.2025Digestive diseases and sciences
  11. ChatGPT-4o outperforms gemini advanced in assisting multidisciplinary decision-making for advanced gastric cancer.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  12. A Golgi apparatus-related signature predicts the immune microenvironment and prognosis of gastric cancer.2025Genes and immunity
  13. P2X7 receptor promotes the growth and metastasis of gastric cancer by activating P13/AKT/GSK-3 beta signaling (experimental research).2025International journal of surgery (London, England)Free full text
  14. The functional role of P2 purinergic receptors in the progression of gastric cancer.2025Purinergic signallingFree full text
  15. Research Progress in Clinical Applications of Gastric Contrast-Enhanced Ultrasound.2025Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  16. Upregulation of E-cadherin by the combination of methionine restriction and HDAC2 intervention for inhibiting gastric carcinoma metastasis.2024Acta biochimica et biophysica SinicaFree full text
  17. Influence of Postoperative Insulin Resistance on Short-Term Outcomes of Radical Gastrectomy for Gastric Cancer: A Microbiome and Metabolome-Based Prospective Cohort Study.2024Annals of surgical oncology
  18. Probiotic Compounds Enhanced Recovery after Surgery for Patients with Distal Gastric Cancer: A Prospective, Controlled Clinical Trial.2024Annals of surgical oncology
  19. PANoptosis subtypes predict prognosis and immune efficacy in gastric cancer.2024Apoptosis : an international journal on programmed cell death
  20. Methionine restriction attenuates the migration and invasion of gastric cancer cells by inhibiting nuclear p65 translocation through TRIM47.2024Biological chemistry
  21. Disulfidptosis signature predicts immune microenvironment and prognosis of gastric cancer.2024Biology directFree full text
  22. The Role of Methionine Restriction in Gastric Cancer: A Summary of Mechanisms and a Discussion on Tumor Heterogeneity.2024BiomoleculesFree full text
  23. Construction of a disulfidptosis-related glycolysis gene risk model to predict the prognosis and immune infiltration analysis of gastric adenocarcinoma.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  24. Methionine restriction promotes cisplatin sensitivity of gastric cancer resistant cells by down-regulating circ-CDK13 level.2024Experimental cell research
  25. KLF10/CBS increases the sensitivity of gastric carcinoma cells to methionine restriction by promoting sulfur transfer pathway.2024Experimental cell research
  26. Inflammatory burden index as a prognostic marker in patients with advanced gastric cancer treated with neoadjuvant chemotherapy and immunotherapy.2024Frontiers in immunologyFree full text
  27. Machine learning to predict distant metastasis and prognostic analysis of moderately differentiated gastric adenocarcinoma patients: a novel focus on lymph node indicators.2024Frontiers in immunologyFree full text
  28. Exosome as a crucial communicator between tumor microenvironment and gastric cancer (Review).2024International journal of oncologyFree full text
  29. Identification roles of NFE2L3 in digestive system cancers.2024Journal of cancer research and clinical oncologyFree full text
  30. The relationship between periodontal disease and gastric cancer: A bidirectional Mendelian randomization study.2024MedicineFree full text
  31. A degradome-related signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma based on machine learning procedure.2024MedicineFree full text
  32. Machine learning-based cell death signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma.2024MedicineFree full text
  33. Development and external validation of a nomogram predicting overall survival for Gastric adenocarcinoma patients with radical gastrectomy.2024Scandinavian journal of gastroenterology
  34. Role of P2X7 receptor in the progression and clinicopathological characteristics of gastric cancer.2024Scientific reportsFree full text
  35. An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma.2023Apoptosis : an international journal on programmed cell death
  36. AKT/GSK-3beta/VEGF signaling is involved in P2RY2 activation-induced the proliferation and metastasis of gastric cancer.2023Carcinogenesis
  37. Landscapes and mechanisms of CD8+ T cell exhaustion in gastrointestinal cancer.2023Frontiers in immunologyFree full text
  38. Target tumor therapy in human gastric cancer cells through the combination of docetaxel-loaded cationic lipid microbubbles and ultrasound-triggered microbubble destruction.2023Functional & integrative genomics
  39. SKAP1 Is a Novel Biomarker and Therapeutic Target for Gastric Cancer: Evidence from Expression, Functional, and Bioinformatic Analyses.2023International journal of molecular sciencesFree full text
  40. LncRNA POU6F2-AS2 contributes to malignant phenotypes and paclitaxel resistance by promoting SKP2 expression in stomach adenocarcinoma.2023Journal of chemotherapy (Florence, Italy)
  41. Cancer functional states-based molecular subtypes of gastric cancer.2023Journal of translational medicineFree full text
  42. Identification of a basement membrane-related genes signature to predict prognosis, immune landscape and guide therapy in gastric cancer.2023MedicineFree full text
  43. Toll-like receptor 3 is a potential prognosis marker and associated with immune infiltration in stomach adenocarcinoma.2022Cancer biomarkers : section A of Disease markersFree full text
  44. Clostridium butyricum potentially improves inflammation and immunity through alteration of the microbiota and metabolism of gastric cancer patients after gastrectomy.2022Frontiers in immunologyFree full text
  45. The Hypoxic Landscape Stratifies Gastric Cancer Into 3 Subtypes With Distinct M6a Methylation and Tumor Microenvironment Infiltration Characteristics.2022Frontiers in immunologyFree full text
  46. Meta-analysis of the prognostic value of circulating tumor cells in gastrointestinal cancer.2022MedicineFree full text
  47. The circadian clock is associated with prognosis and immune infiltration in stomach adenocarcinoma.2021AgingFree full text
  48. Constructing a new prognostic signature of gastric cancer based on multiple data sets.2021BioengineeredFree full text
  49. Establishment of a prognostic model of four genes in gastric cancer based on multiple data sets.2021Cancer medicineFree full text
  50. USP1 Promotes GC Metastasis via Stabilizing ID2.2021Disease markersFree full text
  51. Transfer of LncRNA CRNDE in TAM-derived exosomes is linked with cisplatin resistance in gastric cancer.2021EMBO reportsFree full text
  52. Adjuvant treatment and molecular mechanism of probiotic compounds in patients with gastric cancer after gastrectomy.2021Food & functionRCT
  53. Establishment of a prognostic model of ten transcription factors in gastric cancer.2021Genomics
  54. Combining the platelet-to-albumin ratio with serum and pathologic variables to establish a risk assessment model for lymph node metastasis of gastric cancer.2021Journal of biological regulators and homeostatic agents
  55. Long noncoding RNA TUG1 upregulates VEGFA to enhance malignant behaviors in stomach adenocarcinoma by sponging miR-29c-3p.2021Journal of clinical laboratory analysisFree full text
  56. Exosome-mediated transfer of lncRNA HCG18 promotes M2 macrophage polarization in gastric cancer.2021Molecular immunology
  57. Methionine deficiency promoted mitophagy via lncRNA PVT1-mediated promoter demethylation of BNIP3 in gastric cancer.2021The international journal of biochemistry & cell biology
Chinese-language papers (not in the count)1
  1. [Expression characteristics and functional analysis of ELK3 in gastric cancer].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status9
  1. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  2. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  3. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early DiagnosisRecruitingNCT06822413Study siteStart 2022-09
  4. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  5. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  6. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  7. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  8. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  9. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 105 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
105
2021–2025
Trials led
9
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
24
led by another institution
Papers led per year
2021: 191920212022: 111120222023: 232320232024: 202020242025: 30302025

4 hospitals in Nanchang for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 29

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
    Phase
    N/A
    Started
    2026-02
    Posted
    Registry
    NCT07398599

    Age 18 years to 99 years (registered criteria)

    Led by Second Affiliated Hospital of Nanchang UniversityNanchang

  2. Recruiting
    Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07655622

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Nanchang UniversityNanchang

  3. Recruiting
    SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
    Phase
    Phase 2/Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT07131319

    Age 18 years to 85 years (registered criteria)

    Led by Second Affiliated Hospital of Nanchang UniversityNanchang

  4. Recruiting
    Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06554613

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Nanchang UniversityNanchang

  5. Enrolling by invitation
    Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06773156

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Nanchang UniversityNanchang

  6. Recruiting
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07222566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  7. Recruiting
    A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07361497

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Shantou, Shenzhen, Suzhou, Taiyuan, Taizhou, Xi'an, Zhengzhou

  8. Recruiting
    A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07361510

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shantou

  9. Recruiting
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07472517

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou

  10. Recruiting
    A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07541170

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changchun, Chengdu, Foshan, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Shenzhen, Suzhou, Taizhou, Tianjin

  11. Recruiting
    Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06801834

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Shanghai, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  12. Recruiting
    A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06875310

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou

  13. Recruiting
    A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06892548

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Xi'an, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yichang, Zhengzhou

  14. Recruiting
    Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT06899126

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou

  15. Recruiting
    A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07111520

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou

  16. Recruiting
    IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07198841

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Foshan, Guangzhou, Nanchang, Nanning, Shijiazhuang

  17. Recruiting
    PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
    Phase
    Not given
    Started
    2025-10
    Posted
    Registry
    NCT07775820

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 4 listed hospitals as study sitesGuangzhou, Nanchang, Shenzhen, Wenzhou

  18. Recruiting
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT05956587

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Luoyang, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou

  19. Recruiting
    A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2024-01
    Posted
    Registry
    NCT06179069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Wuhan, Xi'an, Xiamen, Zhengzhou

  20. Recruiting
    A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06203210

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Shenyang, Tianjin, Urumqi, Wuhan, Xiangyang, Yantai, Zhengzhou

  21. Recruiting
    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06345729

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou

  22. Recruiting
    Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
    Phase
    Phase 3
    Started
    2024-06
    Posted
    Registry
    NCT06422143

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanchang, Shanghai, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou

  23. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  24. Recruiting
    DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT05882058

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Hangzhou, Jinan, Nanchang, Shanghai

  25. Recruiting
    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT06095583

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou

  26. Recruiting
    Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06170788

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou

  27. Recruiting
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2022-03
    Posted
    Registry
    NCT04928846

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  28. Not yet recruiting
    A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07833202

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanchang

  29. Not yet recruiting
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT05767892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicineRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led105
  1. SLBP promotes lung adenocarcinoma progression by inhibiting ferroptosis and reprogramming glutamine metabolism via FADS2 interaction.2026Experimental cell research
  2. Per- and polyfluoroalkyl substances induce cytotoxicity in NCI-H446 cells through modulating proliferation, apoptosis, and m6A methylation.2026Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  3. Development and validation of nomogram for predicting the cancer-specific survival among patients aged 80 and above with early-stage non-small cell lung cancer.2025ANZ journal of surgery
  4. Dual-energy CT Radiomics Combined with Quantitative Parameters for Differentiating Lung Adenocarcinoma From Squamous Cell Carcinoma: A Dual-center Study.2025Academic radiology
  5. Tracheal, bronchus, and lung cancer among older adults: thirty-year global burden trends, precision medicine breakthroughs, and lingering barriers.2025BMC cancerFree full text
  6. The added value of quantitative contrast-enhanced CT parameters in distinguishing malignant from benign solid pulmonary nodules.2025BMC medical imagingFree full text
  7. Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancer.2025Cancer
  8. Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study.2025Cancer immunology, immunotherapy : CIIFree full text
  9. Opportunities and challenges for non-small cell lung cancer brain metastases in the immunotherapy era.2025Cancer treatment reviews
  10. Targeting SHP2 to reverse immune evasion and resistance to anti-PD-1 therapy in non-small cell lung cancer.2025Cell communication and signaling : CCSFree full text
  11. Combining serum CDK1 with tumor markers for the diagnosis of small cell lung cancer.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  12. GBP2 regulates lung cancer progression through STAT1 and impacts glycolysis.2025Clinical and experimental medicineFree full text
  13. Identification and external validation of a prognostic signature based on MAPK-related genes to evaluate survival prognosis and treatment efficacy in lung adenocarcinoma.2025Clinical and experimental medicineFree full text
  14. Innovative technologies and their clinical prospects for early lung cancer screening.2025Clinical and experimental medicineFree full text
  15. Cancer-associated Fibroblasts (CAFs) Regulate Lung Cancer Malignant Progression by Transferring SERPINE2 (PN1) via Exosomes.2025Current molecular medicine
  16. Decoding the role of lipid metabolism in NSCLC: From macrophage subtype identification to prognostic model development.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  17. The association between triglyceride glucose-body mass index and overall survival in postoperative patient with lung cancer.2025Frontiers in endocrinologyFree full text
  18. PSMD14 drives lung adenocarcinoma progression through HMMR stabilization and dual activation of TGF-β/Smad and PI3K/AKT/mTOR signaling.2025Frontiers in immunologyFree full text
  19. Integrative multi-omics reveals energy metabolism-related prognostic signatures and immunogenetic landscapes in lung adenocarcinoma.2025Frontiers in immunologyFree full text
  20. Progress in lung cancer study coupled with cognitive frailty in elderly individuals.2025Geriatric nursing (New York, N.Y.)
  21. Mediation of macrophage M1 polarization dynamics change by ubiquitin-autophagy-pathway regulated NLRP3 inflammasomes in PD-1 inhibitor-related myocardial inflammatory injury.2025Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  22. Unraveling molecular characteristics and functional exploration of panoptosis for prognosis stratification in lung adenocarcinoma: a tumor marker prognostic study.2025International journal of surgery (London, England)Free full text
  23. Bidirectional mendelian randomization and single-cell sequencing reveal T cell-mediated causal links between COPD and lung adenocarcinoma.2025International journal of surgery (London, England)
  24. Assessing the Therapeutic Value of Primary Tumor Resection in Colorectal Cancer Lung Metastases: A Dynamic Visualization Clinical Tool Constructed Based on the SEER Database.2025Journal of gastroenterology and hepatology
  25. Integrated multi-omics reveals glycolytic gene signatures of lung adenocarcinoma brain metastasis and the impact of Rac2 lactylation on immunosuppressive microenvironment.2025Journal of translational medicineFree full text
  26. Circ_0002638 drives squamous cell lung cancer (LUSC) progression and chemotherapy resistance by inhibiting ferroptosis via SENP1-mediated deSUMOylation of ACSL4.2025Life sciences
  27. Intrathecal Pemetrexed Administration and Myelosuppression in Patients with Leptomeningeal Metastases from Lung Adenocarcinoma: A Retrospective Study.2025Oncology researchFree full text
  28. P21 activated kinase 6: a promising tool for predicting small cell lung cancer diagnosis and treatment response.2025PeerJFree full text
  29. Comprehensive exploration of programmed cell death landscape in lung adenocarcinoma combining multi-omic analysis and experimental verification.2025Scientific reportsFree full text
  30. FHL2 facilitates LUSC growth and therapy resistance through PI3K/AKT/mTOR activation.2025The Journal of biological chemistryFree full text
  31. Primary tumor resection: a new hope or an old illusion for patients with metastatic non-small cell lung neuroendocrine tumors?2025World journal of surgical oncologyFree full text
  32. Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysis.2025World journal of surgical oncologyFree full text
  33. Upregulation of E-cadherin by the combination of methionine restriction and HDAC2 intervention for inhibiting gastric carcinoma metastasis.2024Acta biochimica et biophysica SinicaFree full text
  34. Crizotinib resistance reversal in ALK-positive lung cancer through zeolitic imidazolate framework-based mitochondrial damage.2024Acta biomaterialia
  35. Prognostic value and immune landscapes of anoikis-associated lncRNAs in lung adenocarcinoma.2024AgingFree full text
  36. Machine learning predictive models and risk factors for lymph node metastasis in non-small cell lung cancer.2024BMC pulmonary medicineFree full text
  37. Abnormal expression of LCA and CD43 in SCLC: a rare case report and brief literature review.2024BMC pulmonary medicineFree full text
  38. KLF10/CBS increases the sensitivity of gastric carcinoma cells to methionine restriction by promoting sulfur transfer pathway.2024Experimental cell research
  39. Tumor lymphangiogenesis index reveals the immune landscape and immunotherapy response in lung adenocarcinoma.2024Frontiers in immunologyFree full text
  40. Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs.2024International journal of cancer
  41. Vitamin D-mediated tsRNA-07804 triggers mitochondrial dysfunction and suppresses non-small cell lung cancer progression by targeting CRKL.2024Journal of cancer research and clinical oncologyFree full text
  42. Comparison of clinical outcomes in patients with advanced pulmonary sarcomatoid carcinoma treated with immunotherapy-based regimens or chemotherapy: A study based on the SEER database and multicentric real-world settings.2024Journal of cancer research and therapeutics
  43. Early death incidence and prediction in stage IV large cell neuroendocrine carcinoma of the lung.2024MedicineFree full text
  44. A practical nomogram for predicting early death in elderly small cell lung cancer patients: A SEER-based study.2024MedicineFree full text
  45. Clinical features and prognostic factors of IV combined small cell lung cancer: A propensity score matching analysis.2024PloS oneFree full text
  46. Treatment strategies for stage IA non-small cell lung cancer: A SEER-based population study.2024PloS oneFree full text
  47. Identification of effective diagnostic genes and immune cell infiltration characteristics in small cell lung cancer by integrating bioinformatics analysis and machine learning algorithms.2024Saudi medical journalFree full text
  48. Douyin and Bilibili as sources of information on lung cancer in China through assessment and analysis of the content and quality.2024Scientific reportsFree full text
  49. Gefitinib metabolism-related lncRNAs for the prediction of prognosis, tumor microenvironment and drug sensitivity in lung adenocarcinoma.2024Scientific reportsFree full text
  50. Effects of preoperative needle biopsy for lung cancer on survival and recurrence: a systematic review and meta-analysis.2024Surgery today
  51. Risk of COVID-19 infection in patients with NSCLC receiving EGFR-TKI targeted therapy during the first wave in China.2024The Journal of international medical researchFree full text
  52. A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in lung adenocarcinoma.2024The journal of gene medicine
  53. Association of immune-related adverse events with COVID-19 pneumonia in lung cancer patients receiving immune checkpoint inhibitors: a cross-sectional study in China.2023BMC cancerFree full text
  54. Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study.2023BMC cancerFree full text
  55. ERCC6 plays a promoting role in the progression of non-small cell lung cancer.2023Biochemistry and cell biology = Biochimie et biologie cellulaire
  56. Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy.2023Biochimica et biophysica acta. Reviews on cancer
  57. Circular RNA hsa_circ_0004689 (circSWT1) promotes NSCLC progression via the miR-370-3p/SNAIL axis by inducing cell epithelial-mesenchymal transition (EMT).2023Cancer medicineFree full text
  58. Circulating hsa_circ_0072309, acting via the miR-100/ACKR3 pathway, maybe a potential biomarker for the diagnosis, prognosis, and treatment of brain metastasis from non-small-cell lung cancer.2023Cancer medicineFree full text
  59. TTI1 promotes non-small-cell lung cancer progression by regulating the mTOR signaling pathway.2023Cancer scienceFree full text
  60. SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.2023Cell death & diseaseFree full text
  61. Delta-like ligand 3 in small cell lung cancer: Potential mechanism and treatment progress.2023Critical reviews in oncology/hematology
  62. Efficacy of PD-1 Inhibitors Combined with Anti-Angiogenic Therapy in Driver Gene Mutation Negative Non-Small-Cell Lung Cancer with Brain Metastases.2023Discovery medicine
  63. The value of serum TRAP1 in diagnosing small cell lung cancer and tumor immunity.2023Experimental biology and medicine (Maywood, N.J.)Free full text
  64. Immune Checkpoint Inhibitors and Tuberculosis Infection in Lung Cancer: A Case Series and Systematic Review With Pooled Analysis.2023Journal of clinical pharmacology
  65. D-D and PLR, NLR combined forecasting first-line treatment: The short-term curative effect and prognosis of patients with SCLC.2023MedicineFree full text
  66. The influence of different sequences of vessel ligation on long-term survival during video-assisted thoracoscopic lobectomy for non-small cell lung cancer: A matched cohort study.2023MedicineFree full text
  67. Competing risk analysis of cardiovascular-specific mortality in typical carcinoid neoplasms of the lung: A SEER database analysis.2023MedicineFree full text
  68. Prognostic value of lymph node ratio in stage III non-small-cell lung cancer: A retrospective cohort study.2023MedicineFree full text
  69. Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.2023MedicineFree full text
  70. Pulmonary function protection by single-port thoracoscopic segmental lung resection in elderly patients with IA non-small cell lung cancer: A differential matched analysis.2023MedicineFree full text
  71. Five-hub genes identify potential mechanisms for the progression of asthma to lung cancer.2023MedicineFree full text
  72. Better survival and prognosis in SCLC survivors after combined second primary malignancies: A SEER database-based study.2023MedicineFree full text
  73. Uniportal versus multiportal video-assisted thoracoscopic segmentectomy for non-small cell lung cancer: a systematic review and meta-analysis.2023Surgery today
  74. Comparative analysis of methodologies for predicting overall survival in patients with non-small cell lung cancer based on the number and rate of resected positive lymph nodes: A study based on the SEER database for 2010 through 2019.2023The clinical respiratory journalFree full text
  75. Surgery for stage IIB-IIIB small cell lung cancer.2023World journal of surgical oncologyFree full text
  76. TYK2 is a prognostic biomarker and associated with immune infiltration in the lung adenocarcinoma microenvironment.2022Asia-Pacific journal of clinical oncology
  77. Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study.2022BMC cancerFree full text
  78. A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma.2022BMC cancerFree full text
  79. PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model.2022International immunopharmacology
  80. CircRPPH1 promotes cell proliferation, migration and invasion of non-small cell lung cancer via the PI3K/AKT and JAK2/STAT3 signalling axes.2022Journal of biochemistry
  81. Application of collagen triple helix repeat containing-1 and mitotic spindle apparatus antibody in small cell lung cancer diagnosis.2022Journal of clinical laboratory analysisFree full text
  82. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.2022Journal of clinical pharmacy and therapeutics
  83. Potential benefit of osismertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer.2022Journal of translational medicineFree full text
  84. Prognostic factors and survival prediction for patients with metastatic lung adenocarcinoma: A population-based study.2022MedicineRCTFree full text
  85. A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.2022MedicineFree full text
  86. The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis.2022Molecular cancerFree full text
  87. DNA methylation of ARHGAP30 is negatively associated with ARHGAP30 expression in lung adenocarcinoma, which reduces tumor immunity and is detrimental to patient survival.2021AgingFree full text
  88. Use of dexamethasone and a 5-HT3 receptor antagonist with or without aprepitant to prevent chemotherapy-induced nausea and vomiting among patients with lung cancer who are treated with platinum-based chemotherapy: a systematic review and me2021Annals of palliative medicine
  89. Necitumumab plus platinum-based chemotherapy versus chemotherapy alone as first-line treatment for stage IV non-small cell lung cancer: a meta-analysis based on randomized controlled trials.2021Annals of palliative medicine
  90. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.2021BMC cancerFree full text
  91. Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.2021BMC cancerFree full text
  92. Potential Role of GST-π in Lung Cancer Stem Cell Cisplatin Resistance.2021BioMed research internationalFree full text
  93. Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2021Chemotherapy
  94. Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib.2021Current problems in cancer
  95. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.2021Journal of clinical pharmacy and therapeutics
  96. Bintrafusp Alfa in the Second-Line Treatment of Patients With NSCLC.2021Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  97. Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib.2021Lung cancer (Amsterdam, Netherlands)
  98. Heat shock protein B8 promotes proliferation and migration in lung adenocarcinoma A549 cells by maintaining mitochondrial function.2021Molecular and cellular biochemistry
  99. Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC.2021Molecular cancerFree full text
  100. Overview of serpin B9 and its roles in cancer (Review).2021Oncology reports
  101. Role of hypoxia‑inducible factor‑2α in lung cancer (Review).2021Oncology reports
  102. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.2021Pharmacological research
  103. Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database.2021Radiation oncology (London, England)Free full text
  104. Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial.2021Thoracic cancerFree full text
  105. The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials.2021World journal of surgical oncologyFree full text
All its trials on ClinicalTrials.gov, any status59
  1. Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 ExpressionRecruitingNCT07655622Lead sponsorPhase 1/Phase 2Start 2026-07
  2. Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudyRecruitingNCT07398599Lead sponsorN/AStart 2026-02
  3. SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLCRecruitingNCT07131319Lead sponsorPhase 2/Phase 3Start 2025-04
  4. Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung CancerEnrolling by invitationNCT06773156Lead sponsorPhase 2Start 2024-11
  5. Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLCRecruitingNCT06554613Lead sponsorPhase 2Start 2024-07
  6. Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal MetastasisStatus unknownNCT04944069Lead sponsorN/AStart 2021-07
  7. Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With GefitinibStatus unknownNCT04358562Lead sponsorPhase 2Start 2020-05
  8. The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLCStatus unknownNCT04193007Lead sponsorPhase 2Start 2019-12
  9. Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung CancerStatus unknownNCT04425681Lead sponsorPhase 2Start 2017-10
  10. A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)RecruitingNCT07361497Study sitePhase 3Start 2026-03
  11. A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)RecruitingNCT07361510Study sitePhase 3Start 2026-03
  12. DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyRecruitingNCT07472517Study sitePhase 3Start 2026-04
  13. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT07222566Study sitePhase 3Start 2026-01
  14. A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C MutationNot yet recruitingNCT07833202Study sitePhase 3Start 2026-10
  15. A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07541170Study sitePhase 3Start 2026-10
  16. Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerRecruitingNCT06801834Study sitePhase 3Start 2025-04
  17. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)RecruitingNCT06875310Study sitePhase 3Start 2025-04
  18. IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C MutationRecruitingNCT07198841Study sitePhase 2Start 2025-11
  19. A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerRecruitingNCT06892548Study sitePhase 1/Phase 2Start 2025-05
  20. Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruitingNCT06899126Study sitePhase 3Start 2025-10
  21. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT07111520Study sitePhase 1/Phase 2Start 2025-09
  22. PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung CancerRecruitingNCT07775820Study siteStart 2025-10
  23. A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerRecruitingNCT06203210Study sitePhase 3Start 2024-05
  24. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Study sitePhase 2Start 2024-01
  25. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)RecruitingNCT06345729Study sitePhase 3Start 2024-05
  26. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  27. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]RecruitingNCT06422143Study sitePhase 3Start 2024-06
  28. A Study of ZL-1310 in Subjects With Small Cell Lung CancerRecruitingNCT06179069Study sitePhase 1Start 2024-01
  29. DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine CancersRecruitingNCT05882058Study sitePhase 2Start 2023-10
  30. Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)RecruitingNCT06095583Study sitePhase 3Start 2023-11
  31. YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsNot yet recruitingNCT05767892Study sitePhase 3Start 2023-05
  32. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)RecruitingNCT06170788Study sitePhase 3Start 2023-12
  33. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT04928846Study sitePhase 3Start 2022-03
  34. Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)Active, not recruitingNCT06305754Study sitePhase 3Start 2024-06
  35. A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerTerminatedNCT06685718Study sitePhase 1Start 2024-12
  36. ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsActive, not recruitingNCT05671510Study sitePhase 3Start 2023-06
  37. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)Active, not recruitingNCT06074588Study sitePhase 3Start 2023-11
  38. Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)Active, not recruitingNCT05609968Study sitePhase 3Start 2023-02
  39. Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)TerminatedNCT05226598Study sitePhase 3Start 2022-03
  40. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  41. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Active, not recruitingNCT05668988Study sitePhase 3Start 2022-12
  42. A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerStatus unknownNCT05042375Study sitePhase 3Start 2022-09
  43. A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung CancerActive, not recruitingNCT05297890Study sitePhase 2Start 2022-05
  44. Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05502237Study sitePhase 3Start 2022-10
  45. Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLCCompletedNCT04768075Study sitePhase 3Start 2021-05
  46. Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerTerminatedNCT04921358Study sitePhase 3Start 2021-07
  47. Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)Active, not recruitingNCT05712902Study sitePhase 2Start 2021-07
  48. Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Active, not recruitingNCT04380636Study sitePhase 3Start 2020-07
  49. A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in ChinaCompletedNCT04830826Study siteStart 2020-07
  50. Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerCompletedNCT04205812Study sitePhase 3Start 2020-09
  51. Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Active, not recruitingNCT04624204Study sitePhase 3Start 2020-12
  52. Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Active, not recruitingNCT03974022Study sitePhase 1/Phase 2Start 2019-07
  53. A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung CancerTerminatedNCT03516084Study sitePhase 3Start 2018-08
  54. A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03178552Study sitePhase 2/Phase 3Start 2017-09
  55. Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in ChinaCompletedNCT03059641Study siteStart 2017-02
  56. PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC PatientsStatus unknownNCT03029858Study siteStart 2017-01
  57. A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) PatientsStatus unknownNCT04237805Study sitePhase 1/Phase 2Start 2016-11
  58. Afatinib in NSCLC With HER2 MutationCompletedNCT02597946Study sitePhase 2Start 2016-03
  59. Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303)CompletedNCT02388919Study sitePhase 2/Phase 3Start 2015-02

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 22 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
22
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 7720232024: 4420242025: 552025

3 hospitals in Nanchang for pancreatic cancer192 hospitals in China for pancreatic cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    Phase
    Not given
    Started
    2022-09
    Posted
    Registry
    NCT06822413

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineGastroenterology / hepatologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led22
  1. The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability.2025Cell death & diseaseFree full text
  2. Prognostic differential subpopulation classification and immunotherapy response prediction in pancreatic cancer patients based on the gene features of necrotizing apoptosis.2025Frontiers in immunologyFree full text
  3. KIFC1 Overexpression Promotes Pancreatic Carcinoma Progression via Stabilising BUB1B.2025Journal of cellular and molecular medicineFree full text
  4. Application of pancreaticojejunostomy without suturing main pancreatic duct in laparoscopic pancreaticoduodenectomy for small main pancreatic duct (≤ 3 mm).2025Langenbeck's archives of surgeryFree full text
  5. Bioinformatics analysis identifies NT5M modulates immune evasion through PD-L1 via CXCL8 in pancreatic adenocarcinoma.2025Scientific reportsFree full text
  6. Identification of STAM-binding protein as a target for the treatment of gemcitabine resistance pancreatic cancer in a nutrient-poor microenvironment.2024Cell death & diseaseFree full text
  7. HKDC1 promotes autophagy and proliferation in pancreatic adenocarcinoma through interaction with PARP1 and poly(ADP-ribosyl)ation.2024Cellular signalling
  8. IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment.2024Molecular cancer therapeutics
  9. PAFAH1B3 is a KLF9 target gene that promotes proliferation and metastasis in pancreatic cancer.2024Scientific reportsFree full text
  10. MicroRNA 211-5p inhibits cancer cell proliferation and migration in pancreatic cancer by targeting BMP2.2023AgingFree full text
  11. Pancreatic adenosquamous carcinoma: A population level analysis of epidemiological trends and prognosis.2023Cancer medicineFree full text
  12. FBXO22 Accelerates Pancreatic Cancer Growth by Deactivation of the Hippo Pathway via Destabilizing LATS2.2023Digestive diseases and sciences
  13. Epidemiological trends for functional pancreatic neuroendocrine tumors: A study combining multiple imputation with age adjustment.2023Frontiers in endocrinologyFree full text
  14. Pan-cancer analysis of Krüppel-like factor 3 and its carcinogenesis in pancreatic cancer.2023Frontiers in immunologyFree full text
  15. Comprehensively prognostic and immunological analysis of snail family transcriptional repressor 2 in pan-cancer and identification in pancreatic carcinoma.2023Frontiers in immunologyFree full text
  16. SLC35F2-SYVN1-TRIM59 axis critically regulates ferroptosis of pancreatic cancer cells by inhibiting endogenous p53.2023Oncogene
  17. FAT10 promotes chemotherapeutic resistance in pancreatic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expression.2022Cell death & diseaseFree full text
  18. Comprehensive analysis of the effects of KIF2C on prognosis, biological functions and immune infiltration in PAAD.2022Tissue & cell
  19. USP28 facilitates pancreatic cancer progression through activation of Wnt/β-catenin pathway via stabilising FOXM1.2021Cell death & diseaseFree full text
  20. E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1.2021Journal of translational medicineFree full text
  21. Vaccinia-related kinase 2 drives pancreatic cancer progression by protecting Plk1 from Chfr-mediated degradation.2021Oncogene
  22. E3 ubiquitin ligase UBR5 promotes pancreatic cancer growth and aerobic glycolysis by downregulating FBP1 via destabilization of C/EBPα.2021Oncogene
All its trials on ClinicalTrials.gov, any status3
  1. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early DiagnosisRecruitingNCT06822413Study siteStart 2022-09
  2. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  3. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 19 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
19
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 5520222023: 4420232024: 4420242025: 332025

4 hospitals in Nanchang for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05646862

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Tianjin, Wuhan

  2. Recruiting
    A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT05894239

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Hangzhou, Jinan, Luoyang, Nanchang, Nanning, Shijiazhuang, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineGastroenterology / hepatologyMedical oncologyPathology / laboratory medicine
Papers it led19
  1. circSCYL2 antagonizes hnRNPA2B1-mediated m6A-chromatin crosstalk to promote ferroptosis and inhibit metastasis of breast cancer to brain.2026International journal of biological macromolecules
  2. Efficacy of fulvestrant and capecitabine as maintenance therapy in patients with HR +/HER2 - metastatic breast cancer benefited from first-line chemotherapy.2026Naunyn-Schmiedeberg's archives of pharmacology
  3. Mapping Knowledge Landscapes and Emerging Trends in Contrast-Enhanced Ultrasound for Breast Cancer: A Bibliometric and Visualization Analysis.2026Ultrasound in medicine & biology
  4. Network pharmacology and in vitro analyses reveal EGCG inhibits breast cancer progression via suppression of the EGFR/Src pathway.2025Biochemical and biophysical research communications
  5. ATP ion channel-type P2X purinergic receptors as a key regulatory molecule in breast cancer progression.2025Pathology, research and practice
  6. Molecular Subtypes and Radiotherapy as Determinants of Survival in Invasive Breast Cancer: Insights from a Single-Center Study.2025Southern medical journal
  7. Predicting efficacy of neoadjuvant chemotherapy in breast cancer patients with synthetic magnetic resonance imaging method MAGiC: An observational cohort study.2024European journal of radiology
  8. Noninvasive identification of HER2-zero, -low, or -overexpressing breast cancers: Multiparametric MRI-based quantitative characterization in predicting HER2-low status of breast cancer.2024European journal of radiology
  9. Butyrate inhibits the malignant biological behaviors of breast cancer cells by facilitating cuproptosis-associated gene expression.2024Journal of cancer research and clinical oncologyFree full text
  10. Exploring the interplay between triple-negative breast cancer stem cells and tumor microenvironment for effective therapeutic strategies.2024Journal of cellular physiology
  11. PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials.2023Cancer chemotherapy and pharmacology
  12. Prediction of sentinel lymph node metastasis in breast cancer by using deep learning radiomics based on ultrasound images.2023MedicineFree full text
  13. Ferroptosis-dependent breast cancer cell-derived exosomes inhibit migration and invasion of breast cancer cells by suppressing M2 macrophage polarization.2023PeerJFree full text
  14. Membrane metalloendopeptidase (MME) is positively correlated with systemic lupus erythematosus and may inhibit the occurrence of breast cancer.2023PloS oneFree full text
  15. E3 ubiquitin ligase RBX1 drives the metastasis of triple negative breast cancer through a FBXO45-TWIST1-dependent degradation mechanism.2022AgingFree full text
  16. RAMP2-AS1 inhibits CXCL11 expression to suppress malignant phenotype of breast cancer by recruiting DNMT1 and DNMT3B.2022Experimental cell research
  17. Trait emotional intelligence and quality of life among breast cancer patients: The mediating role of fear of cancer recurrence.2022International journal of nursing practice
  18. Circ_0000442 functions as a tumor repressor in breast cancer by impacting miR-1229-3p and upregulating ZBTB1.2022Mammalian genome : official journal of the International Mammalian Genome Society
  19. A pan-cancer analysis of the role of hexokinase II (HK2) in human tumors.2022Scientific reportsFree full text
All its trials on ClinicalTrials.gov, any status4
  1. A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyRecruitingNCT05646862Study sitePhase 3Start 2023-06
  2. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruitingNCT05894239Study sitePhase 3Start 2023-09
  3. A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerActive, not recruitingNCT05132582Study sitePhase 3Start 2022-03
  4. Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast CancerCompletedNCT03084237Study sitePhase 3Start 2016-11

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 60 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.9%.

Papers led
60
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 111120212022: 121220222023: 171720232024: 141420242025: 662025

3 hospitals in Nanchang for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryRadiology / nuclear medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led60
  1. FBXL16 regulates TAMs recruitment by mediating cytokine release in gliomas.2025Cancer genetics
  2. STAT3-controlled CHI3L1/SPP1 positive feedback loop demonstrates the spatial heterogeneity and immune characteristics of glioblastoma.2025Developmental cell
  3. Comprehensive multi-omics approach reveals critical genes and immunometabolic networks in glioblastoma.2025International journal of surgery (London, England)
  4. Vincristine exerts antiglioma effects by inhibiting the PI3K/AKT signaling pathway: A mechanistic study based on network pharmacology, bioinformatics analysis, and experimental validation.2025Naunyn-Schmiedeberg's archives of pharmacology
  5. WDR4 promotes glioma progression by regulating cell proliferation and cell cycle via the PI3K/Akt-CDK1/2 signaling pathway.2025Neoplasma
  6. TENT5A Increases Glioma Malignancy and Promotes its Progression.2025Recent patents on anti-cancer drug discovery
  7. Identification of a robust biomarker LAPTM4A for glioma based on comprehensive computational biology and experimental verification.2024AgingFree full text
  8. TBC1D1 represses glioma progression by altering the integrity of the cytoskeleton.2024AgingFree full text
  9. Hypoxia conduces the glioma progression by inducing M2 macrophage polarization via elevating TNFSF9 level in a histone-lactylation-dependent manner.2024American journal of physiology. Cell physiology
  10. Decapping enzyme 2 is a novel immune-related biomarker that predicts poor prognosis in glioma.2024Biotechnology & genetic engineering reviews
  11. Identification of Brain Cell Type-Specific Therapeutic Targets for Glioma From Genetics.2024CNS neuroscience & therapeuticsFree full text
  12. CIA-II is associated with lower-grade glioma survival and cell proliferation.2024CNS neuroscience & therapeuticsFree full text
  13. ZNF384 transcriptionally activated MGST1 to confer TMZ resistance of glioma cells by negatively regulating ferroptosis.2024Cancer chemotherapy and pharmacology
  14. RUNX1-PDIA5 Axis Promotes Malignant Progression of Glioblastoma by Regulating CCAR1 Protein Expression.2024International journal of biological sciencesFree full text
  15. Positive feedback loop of c-myc/XTP6/NDH2/NF-κB to promote malignant progression in glioblastoma.2024Journal of experimental & clinical cancer research : CRFree full text
  16. FAM109B plays a tumorigenic role in low-grade gliomas and is associated with tumor-associated macrophages (TAMs).2024Journal of translational medicineFree full text
  17. The roles of extracellular vesicles in gliomas: Challenge or opportunity?2024Life sciences
  18. PSMB2 plays an oncogenic role in glioma and correlates to the immune microenvironment.2024Scientific reportsFree full text
  19. Endosome-microautophagy targeting chimera (eMIATAC) for targeted proteins degradation and enhance CAR-T cell anti-tumor therapy.2024TheranosticsFree full text
  20. Exosomal HMGB3 released by glioma cells confers the activation of NLRP3 inflammasome and pyroptosis in tumor-associated macrophages.2024Tissue & cell
  21. The HNF4A-CHPF pathway promotes proliferation and invasion through interactions with MAD1L1 in glioma.2023AgingFree full text
  22. Identified RP2 as a prognostic biomarker for glioma, facilitating glioma pathogenesis mainly via regulating tumor immunity.2023AgingFree full text
  23. SLC1A5 is a novel biomarker associated with ferroptosis and the tumor microenvironment: a pancancer analysis.2023AgingFree full text
  24. MAGOH is correlated with poor prognosis and is essential for cell proliferation in lower-grade glioma.2023AgingFree full text
  25. DUSP10 is a novel immune-related biomarker connected with survival and cellular proliferation in lower-grade glioma.2023AgingFree full text
  26. MGME1 associates with poor prognosis and is vital for cell proliferation in lower-grade glioma.2023AgingFree full text
  27. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy.2023BMC cancerFree full text
  28. miR-491-5p regulates the susceptibility of glioblastoma to ferroptosis through TP53.2023Biochemical and biophysical research communications
  29. N6-methyladenosine (m6A)-connected lncRNAs are linked to survival and immune infiltration in glioma patients.2023Bioscience reportsFree full text
  30. PPP1R81 correlates with the survival and cell proliferation in lower-grade glioma.2023Bioscience reportsFree full text
  31. Development and validation of a leukocyte-associated immunoglobulin-like receptor-1 prognostic signature for lower-grade gliomas.2023Cancer medicineFree full text
  32. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy.2023Current pharmaceutical design
  33. RPS14 promotes the development and progression of glioma via p53 signaling pathway.2023Experimental cell research
  34. The role of lysosomal peptidases in glioma immune escape: underlying mechanisms and therapeutic strategies.2023Frontiers in immunologyFree full text
  35. Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies.2023Frontiers in immunologyFree full text
  36. Protein disulfide-isomerase A4 confers glioblastoma angiogenesis promotion capacity and resistance to anti-angiogenic therapy.2023Journal of experimental & clinical cancer research : CRFree full text
  37. Identification of a robust scoring system based on metabolic genes followed by in-depth validation of ATP1A3 in glioma.2023Life sciences
  38. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma.2022AgingFree full text
  39. Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.2022BMC cancerFree full text
  40. DNAJC10 correlates with tumor immune characteristics and predicts the prognosis of glioma patients.2022Bioscience reportsFree full text
  41. Comprehensive analysis of the prognostic and role in immune cell infiltration of MSR1 expression in lower-grade gliomas.2022Cancer medicineFree full text
  42. Hispidulin Enhances Temozolomide (TMZ)-Induced Cytotoxicity against Malignant Glioma Cells In Vitro by Inhibiting Autophagy.2022Computational intelligence and neuroscienceFree full text
  43. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.2022Frontiers in immunologyFree full text
  44. Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.2022Frontiers in immunologyFree full text
  45. CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.2022Frontiers in immunologyFree full text
  46. Radiomics features based on T2-weighted fluid-attenuated inversion recovery MRI predict the expression levels of CD44 and CD133 in lower grade gliomas.2022Future oncology (London, England)
  47. The clinical characteristics and prognostic value of IGFBP6 in glioma.2022Neurological research
  48. Transcriptional Patterns of Lower-Grade Glioma Patients with Distinct Ferroptosis Levels, Immunotherapy Response, and Temozolomide Sensitivity.2022Oxidative medicine and cellular longevityFree full text
  49. Suprasellar Ganglioglioma Arising from the Third Ventricle Floor: A Case Report and Review of the Literature.2022Tomography (Ann Arbor, Mich.)Free full text
  50. A risk signature of four aging-related genes has clinical prognostic value and is associated with a tumor immune microenvironment in glioma.2021AgingFree full text
  51. Evaluation of gliomas peritumoral diffusion and prediction of IDH1 mutation by IVIM-DWI.2021AgingFree full text
  52. Exosomes derived from microRNA-512-5p-transfected bone mesenchymal stem cells inhibit glioblastoma progression by targeting JAG1.2021AgingFree full text
  53. TUBA1C expression promotes proliferation by regulating the cell cycle and indicates poor prognosis in glioma.2021Biochemical and biophysical research communications
  54. Early 2 factor (E2F) transcription factors contribute to malignant progression and have clinical prognostic value in lower-grade glioma.2021BioengineeredFree full text
  55. Identification of an epithelial-mesenchymal transition related long non-coding RNA (LncRNA) signature in Glioma.2021BioengineeredFree full text
  56. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.2021Bioscience reportsFree full text
  57. Expression, methylation and prognostic feature of EMILIN2 in Low-Grade-Glioma.2021Brain research bulletin
  58. Human Mitochondrial Ribosomal RNA Modification-Based Classification Contributes to Discriminate the Prognosis and Immunotherapy Response of Glioma Patients.2021Frontiers in immunologyFree full text
  59. Development of a prognostic index based on immunogenomic landscape analysis in glioma.2021Immunity, inflammation and diseaseFree full text
  60. Circ_CLIP2 promotes glioma progression through targeting the miR-195-5p/HMGB3 axis.2021Journal of neuro-oncology
All its trials on ClinicalTrials.gov, any status1
  1. Combing a Deep Learning-Based Radiomics With Liquid Biopsy for Preoperative and Non-invasive Diagnosis of GliomaCompletedNCT05536024Lead sponsorStart 2022-05

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Nanchang for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

8 hospitals in Nanchang for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 26 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
26
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 4420232024: 111120242025: 552025

7 hospitals in Nanchang for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Over half of these papers are lab or animal studies.

Papers it led26
  1. Reversal of MPPa-PDT Resistance in Osteosarcoma by Targeting ROCK2-Mediated Autophagy.2026Cell proliferationFree full text
  2. Silencing Livin gene expression by RNA interference enhanced the chemotherapeutic sensitivity of drug-resistant osteosarcoma cells to doxorubicin.2025Acta histochemica
  3. Identification and functional characterization of T-cell exhaustion-associated lncRNA AL031775.1 in osteosarcoma: a novel therapeutic target.2025Frontiers in immunologyFree full text
  4. ACSL4 accelerates osteosarcoma progression via modulating TGF-β/Smad2 signaling pathway.2025Molecular and cellular biochemistryFree full text
  5. Downregulation of ferroptosis-related Genes can regulate the invasion and migration of osteosarcoma cells.2025Scientific reportsFree full text
  6. Long non-coding RNA AC133552.2: biomarker and therapeutic target in osteosarcoma via PANoptosis gene screening.2025Scientific reportsFree full text
  7. Bioinformatics analysis and validation of mesenchymal stem cells related gene MT1G in osteosarcoma.2024AgingFree full text
  8. Molecular characterization of Golgi apparatus-related genes indicates prognosis and immune infiltration in osteosarcoma.2024AgingFree full text
  9. LncRNA RPARP-AS1 promotes the progression of osteosarcoma cells through regulating lipid metabolism.2024BMC cancerFree full text
  10. The role of programmed cell death in osteosarcoma: From pathogenesis to therapy.2024Cancer medicineFree full text
  11. New insights into the role of mitophagy related gene affecting the metastasis of osteosarcoma through scRNA-seq and CRISPR-Cas9 genome editing.2024Cell communication and signaling : CCSFree full text
  12. Curcumin suppresses metastasis, invasion, and proliferation in osteosarcoma cells by regulating the EGFR/Src signaling axis.2024International journal of immunopathology and pharmacologyFree full text
  13. USP22 Promotes Osteosarcoma Progression by Stabilising β-Catenin and Upregulating HK2 and Glycolysis.2024Journal of cellular and molecular medicineFree full text
  14. The prognostic value of ubiquitin/ubiquitin-like-related genes along with immune cell infiltration and clinicopathological features in osteosarcoma.2024Journal of orthopaedic surgery and researchFree full text
  15. Hydroxysafflor yellow A induced ferroptosis of Osteosarcoma cancer cells by HIF-1α/HK2 and SLC7A11 pathway.2024Oncology researchFree full text
  16. USP22 as a key regulator of glycolysis pathway in osteosarcoma: insights from bioinformatics and experimental approaches.2024PeerJFree full text
  17. Development and validation of a novel endoplasmic reticulum stress-related lncRNAs signature in osteosarcoma.2024Scientific reportsFree full text
  18. Identification of mitochondrial-related signature and molecular subtype for the prognosis of osteosarcoma.2023AgingFree full text
  19. Molecular characterization of cancer-intrinsic immune evasion genes indicates prognosis and tumour microenvironment infiltration in osteosarcoma.2023AgingFree full text
  20. Deubiquitinating enzyme USP10 promotes osteosarcoma metastasis and epithelial-mesenchymal transition by stabilizing YAP1.2023Cancer medicineFree full text
  21. Exploring the immune microenvironment of osteosarcoma through T cell exhaustion-associated gene expression: a study on prognosis prediction.2023Frontiers in immunologyFree full text
  22. Mechanism and Role of Endoplasmic Reticulum Stress in Osteosarcoma.2022BiomoleculesFree full text
  23. Hsp90 regulates the tumorigenic function of tyrosine protein kinase in osteosarcoma.2022Clinical and experimental pharmacology & physiology
  24. The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Tumour Immune Analysis in Osteosarcoma.2022Computational and mathematical methods in medicineFree full text
  25. Low GNG12 Expression Predicts Adverse Outcomes: A Potential Therapeutic Target for Osteosarcoma.2021Frontiers in immunologyFree full text
  26. Revealing the link between macrophage in microenvironment of osteosarcoma and poor prognosis by utilizing the Integrated analysis.2021Journal of musculoskeletal & neuronal interactionsFree full text
Earlier papers (2016–2020)6
  1. Ubiquitin-like protein FAT10 promotes osteosarcoma growth by modifying the ubiquitination and degradation of YAP1.2020Experimental cell research
  2. ROCK2 promotes osteosarcoma growth and metastasis by modifying PFKFB3 ubiquitination and degradation.2019Experimental cell research
  3. Meta-analysis of alkaline phosphatase and prognosis for osteosarcoma.2017European journal of cancer care
  4. [Effect of ursolic acid on proliferation and apoptosis of human osteosarcoma cell line U2-OS].2017Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  5. Id-1 promotes osteosarcoma cell growth and inhibits cell apoptosis via PI3K/AKT signaling pathway.2016Biochemical and biophysical research communications
  6. High level of αB-crystallin contributes to the progression of osteosarcoma.2016Oncotarget

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Nanchang for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Papers it led1
  1. Expression of DOG1 in peripheral blood cells of patients with gastrointestinal stromal tumor.2021Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
All its trials on ClinicalTrials.gov, any status1
  1. Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world StudyStatus unknownNCT05440357Study siteStart 2022-07

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

4 hospitals in Nanchang for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 10 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.6%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 5520242025: 222025

2 hospitals in Nanchang for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskCAR-T & cell therapyStem cell transplant
Departments in papersPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led10
  1. Serum ferritin as a prognostic biomarker in CAR-T therapy for multiple myeloma: A meta-analysis.2025Biomolecules & biomedicineFree full text
  2. METTL5 regulates SEPHS2-mediated selenoprotein synthesis to promote multiple myeloma survival and progression.2025Cell death & diseaseFree full text
  3. An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously.2024Cancer gene therapyFree full text
  4. lncRNA H19 plays a role in multiple myeloma via interacting with hnRNPA2B1 to stabilize BET proteins by targeting osteoclasts and osteoblasts.2024International immunopharmacology
  5. Exosomal lncRNA NEAT1 Inhibits NK-Cell Activity to Promote Multiple Myeloma Cell Immune Escape via an EZH2/PBX1 Axis.2024Molecular cancer research : MCR
  6. The value of myocardial contraction fraction and long-axis strain to predict late gadolinium enhancement in multiple myeloma patients with secondary cardiac amyloidosis.2024Scientific reportsFree full text
  7. A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma.2024Technology in cancer research & treatmentFree full text
  8. Abnormal expression pattern of lncRNA H19 participates in multiple myeloma bone disease by unbalancing osteogenesis and osteolysis.2023International immunopharmacology
  9. Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway.2021BMC cancerFree full text
  10. Multiple myeloma with CD138 changed from positive to negative: A case report.2021Cytometry. Part B, Clinical cytometry
All its trials on ClinicalTrials.gov, any status3
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 15 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
15
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 4420232024: 3320242025: 332025

3 hospitals in Nanchang for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Enrolling by invitation
    A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT07348575

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Nanchang UniversityNanchang

  2. Recruiting
    A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT06973187

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou

  3. Recruiting
    An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07200375

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRheumatology & immunologyMedical oncologyRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led15
  1. Clonal hematopoiesis of indeterminate potential (CHIP): A potential contributor to lymphoma.2025Critical reviews in oncology/hematology
  2. An analysis of the relationship of triglyceride glucose index with diffuse large B-cell lymphoma prognosis: a retrospective study.2025Frontiers in endocrinologyFree full text
  3. Targeting epigenetic reprogramming in DLBCL and its interaction with the tumor microenvironment for novel therapeutic approaches.2025International immunopharmacology
  4. The role of the gut microbiota in infectious complications during immunochemotherapy for diffuse large B-cell lymphoma.2024BMC cancerFree full text
  5. Prognostic value of geriatric nutritional risk index in patients with diffuse large B-cell lymphoma: a meta-analysis.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  6. Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: a systematic review and meta-analysis.2024Frontiers in immunologyFree full text
  7. Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma.2023Cell death & diseaseFree full text
  8. Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma.2023Frontiers in immunologyFree full text
  9. Prediction of sentinel lymph node metastasis in breast cancer by using deep learning radiomics based on ultrasound images.2023MedicineFree full text
  10. Identification of the shared gene signatures and molecular pathways in systemic lupus erythematosus and diffuse large B-cell lymphoma.2023The journal of gene medicine
  11. Exploring the molecular mechanisms and shared gene signatures between rheumatoid arthritis and diffuse large B cell lymphoma.2022Frontiers in immunologyFree full text
  12. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.2022Journal of Zhejiang University. Science. BFree full text
  13. Identification of Aging-Related Genes Associated with Prognostic Value and Immune Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.2022Oxidative medicine and cellular longevityFree full text
  14. Simple cholecystectomy is an adequate treatment for grade I T1bN0M0 gallbladder carcinoma: Evidence from 528 patients.2022World journal of gastroenterologyFree full text
  15. CBL aggravates Ang II-induced cardiac hypertrophy via the VHL/HIF-1α pathway.2021Experimental cell research
All its trials on ClinicalTrials.gov, any status10
  1. A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell LymphomaEnrolling by invitationNCT07348575Lead sponsorPhase 3Start 2024-07
  2. An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell LymphomaRecruitingNCT07200375Study siteStart 2025-09
  3. A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT06973187Study sitePhase 3Start 2025-09
  4. A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsActive, not recruitingNCT06970743Study sitePhase 3Start 2025-05
  5. Evaluating Different Doses of Orelabrutinib in MCLCompletedNCT05978739Study sitePhase 2Start 2023-08
  6. Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma PatientsActive, not recruitingNCT05651178Study siteEarly phase 1Start 2022-08
  7. AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)CompletedNCT06511869Study sitePhase 2Start 2022-03
  8. Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT04666038Study sitePhase 3Start 2021-03
  9. Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.Status unknownNCT03720457Study sitePhase 1Start 2018-11
  10. A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)TerminatedNCT01287741Study sitePhase 3Start 2011-07

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Nanchang for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Nanchang for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 3 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 002025

2 hospitals in Nanchang for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & blood flowStroke & bleeding outcomes
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 1 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Nanchang for Wilson disease28 hospitals in China for Wilson disease

No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics (ATP7B)Treatment (chelation, zinc)Diagnosis & copper tests
Departments in papersGastroenterology / hepatologyNephrology
Papers it led1
  1. Membranous nephropathy caused by dimercaptosuccinic acid in a patient with Wilson's disease: a case report and literature review.2023BMC nephrologyFree full text
Chinese-language papers (not in the count)1
  1. [Wilson's disease misdiagnosed as autoimmune hepatitis: a case report and literature review].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 21 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
21
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 7720232024: 3320242025: 662025

3 hospitals in Nanchang for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
    Phase
    N/A
    Started
    2026-05
    Posted
    Registry
    NCT07587099

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Haikou, Harbin, Jinan, Liaocheng, Nanchang, Qingdao, Urumqi

  2. Not yet recruiting
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    Phase
    N/A
    Started
    2021-09
    Posted
    Registry
    NCT04995159

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology
Papers it led21
  1. Developing and validation of the Sexual Fear Scale in Chinese patients with coronary heart disease.2025BMC cardiovascular disordersFree full text
  2. Randomized Controlled Trial Assessing the Efficacy and Safety of a Liposomal Carrier for Low-Dose Dual Antiplatelet Therapy (Clopidogrel and Aspirin) in Coronary Heart Disease Patients.2025Clinical therapeuticsRCT
  3. Relationship between blood pressure and adverse clinical events in patients undergoing percutaneous coronary intervention (PCI): a retrospective analysis.2025European journal of medical researchFree full text
  4. L-shaped association between ankle-brachial index and coronary heart disease in Chinese adults with hypertension.2025European journal of medical researchFree full text
  5. Validation of a Prediction Model From Quantitative Coronary Angiography to Detect Ischaemic Lesions as Evaluated by Invasive Fractional Flow Reserve.2025Heart, lung & circulation
  6. A deep learning model could screen for coronary heart disease from a "pseudo-normal" electrocardiogram.2025MedicineFree full text
  7. Systemic immune-inflammation index and in-stent restenosis in patients with acute coronary syndrome: a single-center retrospective study.2024European journal of medical researchFree full text
  8. Association between body shape index and coronary heart disease in individuals over 20 years old with obese.2024Journal of health, population, and nutritionFree full text
  9. Predictive value of the triglyceride-glucose index for short- and long-term all-cause mortality in patients with critical coronary artery disease: a cohort study from the MIMIC-IV database.2024Lipids in health and diseaseFree full text
  10. Coronary artery spasm treated with intracoronary bioresorbable scaffold implantation under the guidance of treadmill test and optical coherence tomography: A case report.2023Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, IncFree full text
  11. Relationship between Dietary Decanoic Acid and Coronary Artery Disease: A Population-Based Cross-Sectional Study.2023NutrientsFree full text
  12. Coronary CT Angiography-based Morphologic Index for Predicting Hemodynamically Significant Coronary Stenosis.2023Radiology. Cardiothoracic imagingFree full text
  13. Influence of sodium thiosulfate on coronary artery calcification of patients on dialysis: a meta-analysis.2023Renal failureFree full text
  14. Causal effect of gallstone disease on the risk of coronary heart disease or acute myocardial infarction: a Mendelian randomization study.2023Scientific reportsFree full text
  15. Association study of urinary iodine concentrations and coronary artery disease among adults in the USA: National Health and Nutrition Examination Survey 2003-2018.2023The British journal of nutritionFree full text
  16. Sleep Patterns Modify the Association between Vitamin D Status and Coronary Heart Disease: Results from NHANES 2005-2008.2023The Journal of nutrition
  17. Adherence with cardiovascular medications and the outcomes in patients with coronary arterial disease: "Real-world" evidence.2022Clinical cardiologyFree full text
  18. Colchicine may become a new cornerstone therapy for coronary artery disease: a meta-analysis of randomized controlled trials.2022Clinical rheumatology
  19. Sex differences in assessing stenosis severity between physician visual assessment and quantitative coronary angiography.2022International journal of cardiology
  20. Lipid metabolism patterns and relevant clinical and molecular features of coronary artery disease patients: an integrated bioinformatic analysis.2022Lipids in health and diseaseFree full text
  21. The efficacy and safety of rivaroxaban in coronary artery disease patients with heart failure and sinus rhythm: a systematic review and meta-analysis.2021European journal of clinical pharmacology
All its trials on ClinicalTrials.gov, any status8
  1. Glycemic Variability, Gut Microbiota, and Prognosis in T2DM With ACSStatus unknownNCT06573060Lead sponsorStart 2023-07
  2. Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)RecruitingNCT07587099Study siteN/AStart 2026-05
  3. Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS SystemNot yet recruitingNCT04995159Study siteN/AStart 2021-09
  4. FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery DiseaseActive, not recruitingNCT06218485Study siteN/AStart 2024-03
  5. Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World SettingCompletedNCT02565615Study siteStart 2016-06
  6. Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)Status unknownNCT02448524Study sitePhase 3Start 2015-07
  7. A Trial to Evaluate Efficacy of Heart-protecting Musk PillStatus unknownNCT01897805Study sitePhase 4Start 2011-07
  8. Acarbose Cardiovascular Evaluation TrialCompletedNCT00829660Study sitePhase 4Start 2009-02

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 11 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 2220232024: 2220242025: 332025

4 hospitals in Nanchang for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led11
  1. Special type B interrupted aortic arch diagnosis by angiography in an adult patient: a case report.2025Cardiology in the young
  2. Extreme compensatory dilatation of the splanchnic artery caused by congenital coarctation of the abdominal aorta: a case report.2025Journal of medical case reportsFree full text
  3. Topological Distribution of KCNH2 Variants and Genotype-Phenotype Relationship in Patients With Long QT Syndrome.2025Pacing and clinical electrophysiology : PACE
  4. The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients.2024Cardiovascular drugs and therapy
  5. Lactobacillus plantarum 24-7 improves postoperative bloating and hard stools by modulating intestinal microbiota in patients with congenital heart disease: a randomized controlled trial.2024Food & functionRCT
  6. Aorto-ventricular tunnel with three orifices: a unique case report diagnosed by transthoracic echocardiography.2023Cardiovascular ultrasoundFree full text
  7. Characteristics, treatments and survival of pulmonary arterial hypertension associated with congenital heart disease in China: Insights from a national multicenter prospective registry.2023The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  8. Long-segmental middle aortic coarctation: a rare case first diagnosed by transthoracic echocardiography.2022BMC cardiovascular disordersFree full text
  9. Diagnosis of fetal congenitally unguarded tricuspid valve orifice by echocardiography.2022Echocardiography (Mount Kisco, N.Y.)
  10. Abrupt formation of intracardiac thrombus during patent foramen ovale closure by three-dimensional transesophageal echocardiography.2022Echocardiography (Mount Kisco, N.Y.)
  11. A 15-Year-Old Adolescent With Obstructive Shock and Emerging Thrombus.2021JACC. Cardiovascular interventions
Chinese-language papers (not in the count)1
  1. [Pharmacogenetic exploration of genes associated with cardiac ion channel disease].2025Zhonghua xin xue guan bing za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Nanchang for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Study sitePhase 4Start 2026-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Nanchang for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Follicular helper T cells and fibrotic diseases.2025Cellular immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Nanchang for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

1 hospital in Nanchang for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 10 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 1.4%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 3320232024: 1120242025: 442025

4 hospitals in Nanchang for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led10
  1. Efficacy and safety of hydroxychloroquine in IgA nephropathy with nasopharyngeal or intestinal mucosal and non-mucosal infections.2025BMC nephrologyFree full text
  2. IgA vasculitis with nephritis: an overview of the pathogenesis and clinical characteristics.2025Clinical and experimental rheumatology
  3. Glycine decarboxylase advances IgA nephropathy by boosting mesangial cell proliferation through the pyrimidine pathway.2025EMBO molecular medicineFree full text
  4. Glomerular mesangial cells derived complement factor H regulates complement activation, influences cell proliferation, and maintains actin cytoskeleton.2025International immunopharmacology
  5. The efficacy of rituximab in the treatment of IgA vasculitis nephritis.2024Clinical and experimental medicineFree full text
  6. The role of mononuclear phagocyte system in IgA nephropathy: pathogenesis and prognosis.2023Frontiers in immunologyFree full text
  7. New insights into the mucosal immune pathogenesis of IgA nephropathy from the perspective of COVID-19 vaccination.2023QJM : monthly journal of the Association of Physicians
  8. New-onset IgA nephropathy following COVID-19 vaccination.2023QJM : monthly journal of the Association of PhysiciansFree full text
  9. Effectiveness and safety of tacrolimus treatment for IgA nephropathy: A prospective cohort study.2022Medicina clinica
  10. Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy.2021BMC nephrologyFree full text
Earlier papers (2016–2020)2
  1. Differential expression of urinary exosomal microRNAs in IgA nephropathy.2018Journal of clinical laboratory analysis
  2. Efficacy and Safety of Agents in IgA Nephropathy: An Update Network Meta-Analysis.2018Kidney & blood pressure research
All its trials on ClinicalTrials.gov, any status3
  1. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingNCT06774664Study sitePhase 1/Phase 2Start 2025-01
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Nanchang for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Nanchang for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07387549

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Nanchang for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

南昌大学第二附属医院

Second Affiliated Hospital of Nanchang University

南昌

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Nanchang University Second Affiliated Hospital; Second Affiliated Hospital of Nanchang Medical College; second affiliated hospital of Nanchang university; Second Affiliated Hospital of Nanchang University Nanchang; No.2 Affiliated Hospital of Nanchang University

Suggest a correctionDownload the data